|
|
| 08:30-10:20 |
NEW DEVELOPMENTS IN TREATMENT AND PATHOGENSIS OF PD |
|
Chairs: Tatyana Slobodin, Ukraine; Joaquim Ferreira, Portugal |
| 08:30-09:25 |
Debate: Is the improvement of MAO-B-inhibitors clinically relevant? |
|
Capsule: In contrast to L-Dopa and dopamine agonists, MAO-B-inhibitors seem to be less potent. On the other hand they improve patients with wearing-off and they also reduce off-time and increase on-time. In some instances they may cause dyskinesias which can be reduced by L-Dopa dose adjustment |
| 08:30-08:40 |
Host: Heinz Reichmann, Germany |
| 08:40-08:55 |
Yes: Laszlo Vecsei, Hungary |
| 08:55-09:10 |
No: Spiros Konitsiotis, Greece |
| 09:10-09:25 |
Discussion and rebuttals |
|
| 09:25-10:20 |
Debate: Should PD patients with pre-existing imuplsive-compulsive behavior (ICB)'s be actively selected for dopamine agonist treatments? |
| 09:25-09:35 |
Host: Heinz Reichmann, Germany |
| 09:35-09:50 |
Yes: Per Odin, Germany |
| 09:50-10:05 |
No: Angel Sesar, Spain |
| 10:05-10:20 |
Discussion and rebuttals |
|
| 10:35-12:25 |
REEVALUATION OF MODERN AND OLDER TREATMENTS: THE PROS AND CONS |
|
Chairs: Jagdish Sharma, UK; Mário Miguel Rosa, Portugal |
| 10:35-11:30 |
Proposition: Therapies targeting alpha-synuclein will be the treatment of choice in PD |
|
Capsule: Since PD may be an alpha-synuclein spreading disease it may be beneficial to stop the propagation of alpha-synuclein by vaccination |
| 10;35-10:45 |
Host: Heinz Reichmann, Germany |
| 10:45-11:00 |
Yes: Dieter H. Meier, USA |
| 11:00-11:15 |
No: Ruggero G. Fariello, Italy |
| 11:15-11:30 |
Discussion and rebuttals |
|
| 11:30-12:25 |
Debate: Prion-like spreading is a relevant theory for neurdegenerative diseases |
|
Capsule: Several neurodegenerative diseases progress in a distinct anatomical pattern with identified starting points and spread. It has recently been suggested that this is caused by a spread of the pathology in a prion-like mechanism. If correct, this theory is important for the development of disease modifying therapies. Has the prion hypothesis been proven for PD? |
| 11:30-11:40 |
Host: George Perry, USA |
| 11:40-11:55 |
Yes: C. Warren Olanow, USA |
| 11:55-12:10 |
No: Amos D. Korczyn, Israel |
| 12:10-12:25 |
Discussion and rebuttals |
|
| 15:00-17:00 |
IS WHAT WE HAVE ALWAYS WHAT WE NEED IN PD TREATMENT AND EVALUATION? |
|
Chairs: Joao Massano, Portugal; Angel Sesar, Spain |
| 15:00-16:00 |
Debate: Do COMT inhibitors have a future? |
|
Capsule: COMT-inhibitors may come under pressure due to MAO-B-inhibitors and especially safinamide. Thus, it has to be discussed which patients should still receive COMT inhibitors as first line treatment in PD patients with mild dyskinesia and wearing-off |
| 15:00-15:10 |
Host: Alfonso Fasano, Canada |
| 15:00-15:25 |
Yes: Joaquim Ferreira, Portugal |
| 15:25-15:40 |
No: Ubaldo Bonuccelli, Italy |
| 15:40-16:00 |
Discussion and rebuttals |
|
| 16:00-17:00 |
Debate: Duodopa vs. Apomorphine pumps vs. DBS in advanced PD |
|
Capsile: Patients with advanced PD need invasive therapy, but which of the three options is the best choice under which circumstances? |
| 16:00-16:10 |
Duodopa: Per Odin, Germany |
| 16:10-16:25 |
Apomorphine pumps: Fabrizio Stocchi, Italy |
| 16:25-16:40 |
DBS: Ovidiu Bajenaru, Romania |
| 16:40-17:00 |
Discussion and rebuttals |
|
|
PD/MD & NEUROPATHOLOGY |
|
Chair:s Marco Onofrj, Italy; Joaquim Ferreira, Portugal |
| 17:15-18:00 |
Debate: Ultrasound brain lesioning for the treatment of movement disorders? |
|
Capsule: The widespread use of intracerebral electric stimulation is now widely used in advanced PD and other movement disorders, with low morbidity. Recently, brain lesioning with ultrasound has been shown to be effective and does not need anesthesia or craniotomy. Will this method become popular? |
| 17:15-17:25 |
Host: Martin Rabey, Isarel |
| 17:25-17:40 |
Yes: Jose Obeso, Spain |
| 17:40-18:55 |
No: Néstor Gálvez-Jiménez, USA |
| 18:55-19:00 |
Discussion and rebuttals |
|
|
Chair: TBA |
| 09:00-09:20 |
Trophic factors in PD are really useful tools |
|
Martin Rabey, Israel |
